# 2026-12905: FDA Classifies Special Baby Sleep System as Class II

2026-12905, Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep System, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-06-26, effective 2026-06-26; PRIA reads it as touching household money (as of 2026-07-03).

- Canonical: https://policyrisk.com/federal-register/2026-12905
- As of: 2026-07-03
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12905
- Title: Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep System
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 38506
- Published: 2026-06-26
- Effective: 2026-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-03

## In one line

FDA Classifies Special Baby Sleep System as Class II

## Summary

The FDA has officially placed the infant supine sleep system into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make sure the device is safe and effective while making it easier for companies to bring these helpful baby sleep products to market. The new classification took effect on June 26, 2026, but has been in place since March 30, 2023, so manufacturers and parents can breathe easy!

## Abstract

The Food and Drug Administration (FDA) is classifying the infant supine sleep system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the infant supine sleep system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Infant sleep system reclassified to Class II: benefit, medium. The FDA has classified the infant supine sleep system as Class II (special controls). This classification is codified at 21 CFR 880.5690, became applicable on March 30, 2023, and the final order is effective June 26, 2026.
- 510(k) premarket notification still required: cost, medium. Infant supine sleep systems are subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless FDA grants an exemption under section 510(m). This classification remained applicable on March 30, 2023 and the final order is effective June 26, 2026.
- New testing, data, and warning label rules: mixed, medium. The special controls require clinical data and postmarket surveillance, human factors testing, biocompatibility, non-clinical performance testing (including tipping and cleaning compatibility), and specific labeling. Labeling must include a prominent warning that the device has not been demonstrate…
- De Novo classification creates predicate for future devices: benefit, medium. Because the device was classified via the De Novo process, the infant supine sleep system can serve as a predicate device for future substantially equivalent devices, allowing future sponsors to use the less burdensome 510(k) pathway rather than De Novo or premarket approval.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-12905 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/26/2026-12905/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-infant-supine-sleep)
- [2026-12905 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12905.pdf)

## Related
- [Previous: 2026-12904, Medical Devices; Neurological Devices; Classification of the External Lower Ext…](https://policyrisk.com/federal-register/2026-12904)
- [Next: 2026-12913, Cinnamaldehyde in Pesticide Formulations; Exemption From the Requirement for a…](https://policyrisk.com/federal-register/2026-12913)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12905 (as of 2026-07-03).